The post Hong Kong Exchange Fund Posts Record HK$331B Return in 2025 appeared on BitcoinEthereumNews.com. Alvin Lang Jan 28, 2026 08:54 HKMA’s Exchange FundThe post Hong Kong Exchange Fund Posts Record HK$331B Return in 2025 appeared on BitcoinEthereumNews.com. Alvin Lang Jan 28, 2026 08:54 HKMA’s Exchange Fund

Hong Kong Exchange Fund Posts Record HK$331B Return in 2025



Alvin Lang
Jan 28, 2026 08:54

HKMA’s Exchange Fund achieves 8% investment return with record HK$331 billion income as global markets rally. Total assets reach HK$4.15 trillion.

Hong Kong’s Exchange Fund delivered its highest annual investment income on record in 2025, posting HK$331 billion ($42.5 billion) as global equity markets rallied and the weakening US dollar boosted foreign currency holdings.

The Hong Kong Monetary Authority released unaudited figures on January 28 showing the fund achieved an 8% investment return for the year. Total assets grew HK$70.4 billion to reach HK$4.15 trillion, with accumulated surplus standing at HK$936.1 billion.

Where the Gains Came From

Bond holdings led the charge with HK$142.2 billion in gains. Equity positions added another HK$108 billion combined—HK$33.9 billion from Hong Kong stocks and HK$74.1 billion from overseas equities. Currency translation effects contributed HK$38.4 billion as the dollar dropped roughly 9% against major currencies.

The Investment Portfolio returned 12.4%, while the more conservative Backing Portfolio—which defends the Hong Kong dollar peg—gained 5.2%. The Long-Term Growth Portfolio has delivered an 11.2% annualized return since its 2009 inception through September 2025.

Rare Alignment of Positive Returns

HKMA Chief Executive Eddie Yue noted this marks only the third time in 15 years that all major fund components posted positive returns simultaneously—previously occurring in 2017 and 2020. The Hang Seng Index surged 28% in 2025 while the S&P 500 gained 16%, with both benchmarks hitting record highs.

“The exceptional confluence of multiple favourable factors in the global financial markets in 2025 may not last for a long time,” Yue cautioned. He cited AI investment flows, central bank rate cuts, and better-than-expected outcomes from trade conflicts as key 2025 tailwinds.

Context and Outlook

The Exchange Fund, established in 1935, serves as Hong Kong’s monetary defense system—backing banknote issuance and protecting the currency peg from speculative attacks. The fund’s compounded annual return since 1994 stands at 4.5%, outpacing Hong Kong’s 2.0% inflation rate over the same period.

The HKMA recently doubled its RMB Business Facility to RMB200 billion in late January, signaling continued focus on yuan-denominated operations alongside its traditional dollar-based activities.

For 2026, Yue warned that geopolitical tensions, central bank policy shifts, and AI market dynamics could trigger significant volatility. The authority plans to maintain high liquidity levels and defensive positioning while continuing diversification efforts.

Image source: Shutterstock

Source: https://blockchain.news/news/hong-kong-exchange-fund-record-331b-return-2025

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26